The traditional HR Business Partner (HRBP) model, once the gold standard for HR delivery, is undergoing a significant transformation. Many organizations, particularly in industries like pharmaceuticals, are moving towards a more agile resource model, aiming to streamline HR operations and…
HOME > ACADEMIA
ACADEMIA
- Biosimilars Should Be Mentioned in Government Roadmap: JSGM President Muto
October 18, 2012
- Supercomputer to Dramatically Shorten Exploratory Period for Lead Compounds: Prof. Fujitani of University of Tokyo
October 16, 2012
- We Would Like to Provide iPS Cells with Medical History Identification: Prof. Yamanaka of Kyoto University
October 15, 2012
- JAOG Insists on Introduction of HPV Testing to Cervical Cancer Screening
September 14, 2012
- CRND Initiates Clinical Research, Showing Willingness for Company-Sponsored Studies
September 6, 2012
- Incidence of CVD Decreases More in High-Risk Patients with Lower LDL-C during Pravastatin Treatment
July 26, 2012
- 95% of Japanese-Bound Online Drug Sales “Rogue”: LegitScript Survey
July 26, 2012
- Takeda’s TAK-070 for AD Worthy of Clinical Trial: Prof. Iwatsubo of Univ. of Tokyo Hospital
July 18, 2012
- Inlyta Can Be 1st-Choice in 2nd-Line Therapy: Prof. Uemura of Kinki Univ.
July 13, 2012
- Minirinmelt Most Effective for Nocturnal Enuresis, But Precaution for Water Intoxication Needed: Prof. Kaneko
July 11, 2012
- Drug Damage Watchdog Calls for Halt to Easing of Safety Management Procedures for Thalidomide
June 28, 2012
- Univ. of Tokyo Hospital’s New “Phase I Unit” to Initiate Trials for Takeda’s TAK-070 for AD
June 28, 2012
- JSGM Discuss Prices for Long-Listed Products and GEs, Say Unified Prices Could Ruin GE Business
June 26, 2012
- RIKEN, NCC Succeed at Visualizing Kinetics of Trastuzumab in HER2-Positive Breast Cancer Patients
June 7, 2012
- JSN Revises CKD Guidelines; Changes Severity Classifications
May 31, 2012
- Serious ADR for Abatacept shows 2.4%, Lower Than Other RA Drugs: All-Case PMS Interim Analysis
May 7, 2012
- St. Marianna University School of Medicine Hospital to Introduce CDTM, Protocols for Pharmacists to Determine Prescriptions
April 27, 2012
- Remission Rate Equal in Antirheumatic Drugs, Anti-TNF Drugs in JaSTAR’s Interim Analysis
April 26, 2012
- Adoption of NGSP Values for HbA1c Measurement to “Enable Japan’s Leadership in Clinical Trials”: Prof. Kadowaki
April 10, 2012
- Generic Name Prescriptions Rapidly Rise on New Premium, Tokyo Pharmaceutical Association Issues Warning
April 9, 2012
ページ
Japan relies almost entirely on China for the APIs of β-lactam antibiotics. These drugs are essential for treating infectious diseases…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s key reimbursement policy panel on December 25 approved an outline of the FY2025 drug price revision, finalizing plans to…
For the first time in many years, Japan appeared to have pivoted to a pro-innovation path with the FY2024 drug pricing reform. All eyes were apparently on this course change as seen in this year’s most-read story list, though the…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
The Ministry of Health, Labor and Welfare (MHLW) posted the final report compiled by its pharmaceutical regulation panel on its website on April 24, providing cases of drugs that could be exempted from all-case post marketing surveillance (PMS).The MHLW plans…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…